Pro-inflammatory cytokines and related signaling

Pro-inflammatory cytokines and related signaling refers to a broad regulatory network of proteins that initiate and propagate the inflammatory response. Key cytokines in this group include Tumor necrosis factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which are produced by various immune cells such as macrophages and lymphocytes (StatPearls, 2023). These molecules bind to their respective receptors to activate downstream intracellular pathways, most notably the Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), Mitogen-activated protein kinase (MAPK), and Janus kinase/Signal transducer and activator of transcription (JAK/STAT) cascades, leading to the transcription of genes that promote inflammation and immune cell recruitment (Nature Reviews Immunology, 2018). While essential for host defense against pathogens, chronic or excessive activation of these signaling pathways is a primary driver of autoimmune diseases, chronic inflammatory conditions, and cytokine storms (Frontiers in Immunology, 2021). Pharmacological targeting of this network is a cornerstone of modern immunology, utilizing monoclonal antibodies to neutralize ligands or receptors, as well as small molecule inhibitors to block intracellular signal transduction. This therapeutic approach has revolutionized the treatment of conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis by specifically dampening the overactive immune response.

Other names

Inflammatory cytokine signalingPro-inflammatory cascadeCytokine-mediated signaling pathwayInflammatory signaling network

Drugs targeting this network act through several mechanisms: monoclonal antibodies or soluble receptors neutralize circulating cytokines; receptor antagonists block the binding of cytokines to their cell-surface receptors; and small molecule inhibitors target intracellular kinases like Janus kinases (JAKs) to prevent downstream signal transduction (PubMed, 2022).